Latest Tenofovir Stories
A new study from the University of North Carolina at Chapel Hill School of Medicine further validates the use of humanized BLT mice in the fight to block HIV transmission.
An HIV-positive person who takes anti-retroviral drugs immediately after diagnosis, rather than waiting until their health begins to decline, can reduce the risk of spreading the virus to uninfected partners by 96%.
Researchers are stopping tests of a daily pill to prevent infection with the AIDS virus in thousands of African women.
The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis (PrEP) can be implemented on a large scale.
A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests research presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI).
In the first study to make head-to-head comparisons between tenofovir gel and oral tenofovir â€“ two promising approaches for preventing HIV in women â€“ researchers found that daily use of the vaginal gel achieved a more than 100-times higher concentration of active drug in vaginal tissue than did the oral tablet, while, compared to the gel, the tablet used daily was associated with a 20-times higher active drug concentration in blood.
A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum.
PITTSBURGH, Jan. 27, 2011 /PRNewswire/ -- Mylan Inc.
CORK, Ireland, Jan.
WASHINGTON, Dec. 23, 2010 /PRNewswire-USNewswire/ -- On December 17, Science Magazine recognized a promising HIV study as one of the top ten achievements of 2010.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.